CLS (CHARTER LIFE SCIENCES) is an early stage life sciences venture capital investor.

CLS makes initial portfolio company investments in life sciences companies that are seeking capital to obtain initial proof-of-efficacy of their products (see Investment Criteria), and we continue to support our successful portfolio companies with follow on investments until they are acquired or go public.

Our team is led by four Managing Partners who have worked together to create and build life sciences companies for over twenty years. Our team brings extensive scientific, clinical, regulatory, operational and finance experience to each of our portfolio companies.

We play an active role in helping entrepreneurs build successful companies. Our time, energy and passion is devoted to building early stage life sciences opportunities. As a result, your company will be compared only against other early stage opportunities. So, at CLS, your early stage biotech medical device or health care information technology company will not be compared against a PIPE investment in an undervalued Phase III company, as an example. Early stage is what we do, and all we do.


We understand that early stage companies do not have all the answers and do not have all the data. We understand that many basic questions need investment capital to answer, and we understand that development plans and milestones are subject to lots of uncertainty and change. We understand what it takes to build a management team from scratch, and we invest in companies with little or no existing management. In short, we understand what it is to be an early stage entrepreneur, because each of us has been one.

Please look carefully at our investment criteria and our team, and if we are the type of partner that you would like to work with, please contact us.

In the News

KFx Medical, LLC announced that it has entered into a license agreement with CONMED Corporation – CNMD (NASDAQ) relating to its patents used in knotless double row rotator cuff repair. Under the agreement, CONMED and its affiliates will have the right to promote the use of products and techniques for knotless double row rotator cuff repair as claimed in US Patent number 7,585,311 and related patents and applications for the life of those patents. Approximately one-third of more than 400,000 rotator cuff repairs in the United States utilize the technique to achieve an anatomic reattachment of tendon. Terms of the [more]
- Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluates the efficacy of two doses of vaccine candidate TAK-003, administered three months apart, to protect against all four strains of dengue virus, regardless of previous dengue exposure - Study includes children and adolescents ages 4 through 16 years in eight dengue-endemic countries across Latin America and Asia  - Achieving enrollment demonstrates Takeda’s commitment to advancing global vaccine business and addressing unmet needs in dengue prevention Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that it has completed enrollment of 20,100 children and adolescents ages 4 through 16 in its global, pivotal Phase 3 [more]